AKZO NOBEL SPONS.ADRS 1/3 (AKUP) - Net Assets
Based on the latest financial reports, AKZO NOBEL SPONS.ADRS 1/3 (AKUP) has net assets worth €4.82 Billion EUR (≈ $5.64 Billion USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€13.95 Billion ≈ $16.31 Billion USD) and total liabilities (€9.13 Billion ≈ $10.67 Billion USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore AKZO NOBEL SPONS.ADRS 1/3 assets under control for the complete picture of this company's asset base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €4.82 Billion |
| % of Total Assets | 34.56% |
| Annual Growth Rate | 1.97% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 2.78 |
AKZO NOBEL SPONS.ADRS 1/3 - Net Assets Trend (2022–2025)
This chart illustrates how AKZO NOBEL SPONS.ADRS 1/3's net assets have evolved over time, based on quarterly financial data. For live valuation and market cap data, see AKUP market cap.
Annual Net Assets for AKZO NOBEL SPONS.ADRS 1/3 (2022–2025)
The table below shows the annual net assets of AKZO NOBEL SPONS.ADRS 1/3 from 2022 to 2025. Explore cash efficiency ratio of AKZO NOBEL SPONS.ADRS 1/3 to assess how effectively this company generates cash.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | €4.82 Billion ≈ $5.64 Billion |
+0.12% |
| 2024-12-31 | €4.82 Billion ≈ $5.63 Billion |
+5.94% |
| 2023-12-31 | €4.55 Billion ≈ $5.31 Billion |
-0.04% |
| 2022-12-31 | €4.55 Billion ≈ $5.32 Billion |
-- |
Equity Component Analysis
This analysis shows how different components contribute to AKZO NOBEL SPONS.ADRS 1/3's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 55900000000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | €559.00 Million | 12.00% |
| Other Components | €4.10 Billion | 88.00% |
| Total Equity | €4.66 Billion | 100.00% |
AKZO NOBEL SPONS.ADRS 1/3 Competitors by Market Cap
The table below lists competitors of AKZO NOBEL SPONS.ADRS 1/3 ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
GMéxico Transportes S.A.B. de C.V
MX:GMXT
|
$8.58 Billion |
|
Korea Investment Holdings Co
KO:071050
|
$8.58 Billion |
|
Krka d. d
WAR:KRK
|
$8.59 Billion |
|
NMDC Limited
NSE:NMDC
|
$8.59 Billion |
|
ALD SA
PA:AYV
|
$8.57 Billion |
|
Moog Inc
NYSE:MOG-A
|
$8.57 Billion |
|
Huadong Medicine Co Ltd
SHE:000963
|
$8.56 Billion |
|
Meridian Energy Ltd
AU:MEZ
|
$8.55 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in AKZO NOBEL SPONS.ADRS 1/3's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 4,574,000,000 to 4,659,000,000, a change of 85,000,000 (1.9%).
- Net income of 635,000,000 contributed positively to equity growth.
- Dividend payments of 382,000,000 reduced retained earnings.
- Other factors decreased equity by 168,000,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €635.00 Million | +13.63% |
| Dividends Paid | €382.00 Million | -8.2% |
| Other Changes | €-168.00 Million | -3.61% |
| Total Change | €- | 1.86% |
Book Value vs Market Value Analysis
This analysis compares AKZO NOBEL SPONS.ADRS 1/3's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.63x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2022-12-31 | €25.42 | €17.10 | x |
| 2023-12-31 | €25.33 | €17.10 | x |
| 2024-12-31 | €26.78 | €17.10 | x |
| 2025-12-31 | €27.24 | €17.10 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently AKZO NOBEL SPONS.ADRS 1/3 utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 13.63%
- The company shows good efficiency in utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 6.25%
- • Asset Turnover: 0.73x
- • Equity Multiplier: 2.99x
- Recent ROE (13.63%) is above the historical average (10.96%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2022 | 8.12% | 3.25% | 0.74x | 3.40x | €-81.30 Million |
| 2023 | 10.23% | 4.14% | 0.73x | 3.37x | €9.80 Million |
| 2024 | 11.85% | 5.06% | 0.75x | 3.12x | €84.60 Million |
| 2025 | 13.63% | 6.25% | 0.73x | 2.99x | €169.10 Million |
Industry Comparison
This section compares AKZO NOBEL SPONS.ADRS 1/3's net assets metrics with peer companies in the Specialty Chemicals industry.
Industry Context
- Industry: Specialty Chemicals
- Average net assets among peers: $2,825,529,489
- Average return on equity (ROE) among peers: -45.63%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| AKZO NOBEL SPONS.ADRS 1/3 (AKUP) | €4.82 Billion | 8.12% | 1.89x | $8.57 Billion |
| GRAPHENE MANUFACT.GROUP (0GF) | $8.69 Million | -107.23% | 0.84x | $152.93 Million |
| Orion Engineered Carbons SA (0OE) | $55.62 Million | 84.39% | 17.88x | $318.41 Million |
| H&R GmbH & Co. KGaA (2HRA) | $346.88 Million | -2.60% | 1.15x | $183.88 Million |
| Dotz Nano Ltd (57N) | $3.79 Million | -160.22% | 0.25x | $3.81 Million |
| EXPLOS. PROD. CHIM.EO 31 (9Z50) | $144.93 Million | 14.73% | 2.07x | $536.15 Million |
| Altech Chemicals Ltd (A3Y) | $33.88 Million | -176.29% | 0.32x | $27.76 Million |
| AlzChem Group AG (ACT) | $258.23 Million | 24.57% | 1.39x | $1.83 Billion |
| AIR LIQUIDE ADR 1/5/EO 11 (AILA) | $24.57 Billion | 11.23% | 1.02x | $103.86 Billion |
| BRAIN Biotech AG (BNN) | $5.76 Million | -99.29% | 4.28x | $51.56 Million |
About AKZO NOBEL SPONS.ADRS 1/3
Akzo Nobel N.V. produces and sells paints and coatings worldwide. It operates through Decorative Paints and Performance Coatings segments. The company offers decorative paints, including paints, enamels, varnishes, and surface preparation products; and a range of mixing machines, color concepts and advice, and training for applicators. It also provides performance coatings that produces engineere… Read more